Qing-Sheng,Mi, MD, PhD
Editor in Chief
Qing-Sheng,Mi, MD, PhD
Professor and Director

Department of Dermatology and Internal Medicine
Wayne State University
USA

Education

1992 Ph.D in Immunology and Dermatology China Medical University ,Shenyang/Liaonin, P. R. China
1991 M.S. in Immunology and Dermatology Second Military Medical University, Shanghai, P. R. China
1985 M.D, Taishan Medical University Taian, Shandong, P. R. China

Biography

Qing-Sheng Mi, M.D., Ph.D., is a professor and senior scientist, Director of Henry Ford Immunology Program, Director of Dermatology Research, Dept of Dermatology, Dept of Internal Medicine, Henry Ford Health System (HFHS); Dept of Immunology and Microbiology, dept. of Oncology, Karmanos Cancer Institute (KCI), Wayne State University (WSU). He is also Director of Immunology Focus Group, WSU/KCI/WSU. Dr. Mi received his M.D. from Taishan Medical College in 1985 and his Ph.D. in Immunodermatology from China Medical University in 1992. He was an Assistant Professor, Associate Professor and Professor, Dept of Dermatology, Taishan Medical College (1991-1996); a visiting Associate Scientist, Laboratory of Immunology, National Aging Institute/NIH supported by NIH Fogarty International Scholarship (1996-2000); Senior Research Associate, Autoimmunity Group, Robert Research Institute in Canada (2000-2003); Assistant Professor and Associate professor in Dept of Pathology and Dept of Dermatology, Medical College of Georgia (2003-2008). Since 2008, he joined in Henry Ford Health System and Dept of Immunology and Microbiology, Wayne State University, and established Henry Ford Immunology Program, and was promoted to a Senior Scientist/professor in 2013. Dr. Mi is an author on over 100 publications, and serves as associate editors or member of editorial boards in numerous Journals. He is a grant reviewer for NIH (USA), NSF (China), MRC (United Kingdom), BBRC (United Kingdom), and SNFS (Switzerland). His current research projects include epigenetic (miRNAs/HDACs) immune regulation (especially in NKT cells and epidermal langerhans cells) and miRNA biomarkers for human diseases, which are currently funded by NIH 3 RO1s and Juvenile Diabetes Research Foundation International (JDRF).


Research Interest

  • Immune regulation
  •  NKT cells,
  • Dendritic cells,
  • miRNAs,
  • Skin diseases,
  • Autoimmune diseases,
  • Biomarkers

Professional Activities:

  • Laboratory Travel Award, Annual meeting of AAI, New Orleans 2015
  • This award recognizes research excellence and achievement by AAI (about 20 awards)
  • Member of Steering Committee, Biomarker Working Group 2013
  • Juvenile Diabetes Research Foundation International (about 10 members)
  • Laboratory Travel Award, 2012 Annual meeting, AAI, Boston 2012
  • This award recognizes research excellence and achievement by AAI (about 50 awards)
  • Laboratory Travel Award, 2011 Annual meeting, AAI, San Francisco 2011
  • This award recognizes research excellence and achievement by AAI (about 50 awards)
  • Junior Faculty Travel Award, 2006 Annual meeting, AAI, Boston 2006
  • This award recognizes research excellence and achievement by AAI (about 50 awards)
  • Junior Faculty Travel Award, Annual meeting, 2005
  • American Association of Immunologist (AAI), San Diego
  • This award recognizes research excellence and achievement by AAI (about 50 awards)
  • Junior Faculty Travel Award, 12th International Congress of Immunology 2004
  • Montreal, Canada
  • This award recognizes research excellence and achievement by AAI (about 50 awards)
  • Scholar of “Sunshine program” for oversea scientists 2000
  • Ministry of Education, P. R. China. (15 awards annually)
  • NIH John Fogarty International Scholarship for Foreign Scientists, MD 1996-2000
  • Staff recognition award by National Institutes of Health (1999, MD, USA)
  • The third prize of the Advancement of Science and Technology, 1995
  • The Ministry of Education, P. R. China, Beijing
  • Taian City’s top ten young talent scientists, Taian 1994
  • The first prize of the Advancement of Science and Technology, 1994
  • The Education Committee Shandong Province, Jinan
  • The first prize of the Advancement of Science and Technology 1994 Taishan Medical college, Taian
  • Nominated 1993 Shandong Province’s top ten talent youngster, Jinan 1993
  • The third prize of the Advancement of Science and Technology 1993
  • Shandong Province Education Committee, Jinan
  • Young Scientist Scholarship by 18th Word Congress of Dermatology, NY, USA 1992
  • This award recognizes research excellence and achievement (about 10 awards)

Publications

  1. Wei Q, Liu Y, Liu P, Hao J, Liang M, Mi QS, Chen JK, Dong Z. (2016) MicroRNA-489 Induction by Hypoxia-Inducible Factor-1 Protects against Ischemic Kidney Injury. J Am Soc Nephrol. 2016 Mar 14. pii: ASN.2015080870 PMID: 26975439 .
  2. St Louis D, Romero R, Plazyo O, Arenas-Hernandez M, Panaitescu B, Xu Y, Milovic T, Xu Z, Bhatti G, Mi QS, Drewlo S, Tarca AL, Hassan SS, Gomez-Lopez N. (2016) Invariant NKT Cell Activation Induces Late Preterm Birth That Is Attenuated by Rosiglitazone. J Immunol. 2016 Feb 1;196(3):1044-59. Doi PMID: 26602058.
  3. Waibel JS, Mi QS, Ozog D, Qu L, Zhou L, Rudnick A, Al-Niaimi F, Woodward J, Campos V, Mordon S. Laser-assisted delivery of vitamin C, vitamin E, and ferulic acid formula serum decreases fractional laser postoperative recovery by increasedbeta fibroblast growth factor expression. Lasers Surg Med. 2015 Nov 27. PubMed PMID: 26612341.
  4. Li C, Li Z, Liu S, Wang C, Han L, Cui L, Zhou J, Zou H, Liu Z, Chen J, Cheng X, Zhou Z, Ding C, Wang M, Chen T, Cui Y, He H, Zhang K, Yin C, Wang Y, Xing S, Li B, Ji J, Jia Z, Ma L, Niu J, Xin Y, Liu T, Chu N, Yu Q, Ren W, Wang X, Zhang A, Sun Y, Wang H, Lu J, Li Y, Qing Y, Chen G, Wang Y, Zhou L, Niu H, Liang J, Dong Q, Li X, Mi QS, Shi Y. Genome-wide association analysis identifies three new risk loci for gout arthritis in Han Chinese. Nat Commun. 2015 May 13;6:7041. PubMed Central PMCID: PMC4479022.
  5. Zhou L, Shi YL, Li K, Hamzavi I, Gao TW, Huggins RH, Lim HW, Mi QS. Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development. Pigment Cell Melanoma Res. 2015 May;28(3):324-9. doi: 10.1111/pcmr.12355. Epub 2015 Feb 13. PubMed PMID: 25604047.
  6. Bhatt K, Wei Q, Pabla N, Dong G, Mi QS, Liang M, Mei C, Dong Z. MicroRNA-687 Induced by Hypoxia-Inducible Factor-1 Targets Phosphatase and Tensin Homolog in Renal Ischemia-Reperfusion Injury. J Am Soc Nephrol. 2015 Jul;26(7):1588-96. PubMed PMID: 25587068; (involved in study conception, design, and implementation) .
  7. Barrie ES, Lodder M, Weinreb PH, Buss J, Rajab A, Adin C, Mi QS, Hadley GA. Role of ITGAE in the development of autoimmune diabetes in non-obese diabetic mice. J Endocrinol. 2015 Mar;224(3):235-43. PMID: 25525188. (involved in study conception, design, and implementation).
  8. Dzinic SH, Chen K, Thakur A, Kaplun A, Bonfil RD, Li X, Liu J, Bernardo MM, Saliganan A, Back JB, Yano H, Schalk DL, Tomaszewski EN, Beydoun AS, Dyson G, Mujagic A, Krass D, Dean I, Mi QS, Heath E, Sakr W, Lum LG, Sheng S. Maspin expression in prostate tumor elicits host anti-tumor immunity. Oncotarget. 2014 30;5(22):11225-36. PubMed PMID: 25373490; (involved in study conception, design, and implementation) .
  9. Sun R, Zhang K, Zhang X, Cui L, Wang C, Mi Q, Liu S, Li C. The CC chemokine ligand 2 (CCL2) polymorphism -2518A/G is associated with gout in the Chinese Han male population. Rheumatol Int. 2015 Mar;35(3):479-84. PubMed PMID: 25119828. (involved in study conception, design, and implementation).
  10. Liu X, Gao N, Dong C, Zhou L, Mi QS, Standiford TJ, Yu FS. Flagellin-induced expression of CXCL10 mediates direct fungal killing and recruitment of NK cells to the cornea in response to Candida albicans infection. Eur J Immunol. 2014 Sep;44(9):2667-79.. PubMed PMID:24965580; (involved in study conception, design, and implementation).
  11. Shi YL, Weiland M, Lim HW, Mi QS*, Zhou L*. Serum miRNA expression profiles change in autoimmune vitiligo in mice. Exp Dermatol. 2014 Feb;23(2):140-2. PubMed PMID: 24401108. Co-Senior authors.
  12. Zhou L, Qi RQ, Liu M, Xu YP, Li G, Weiland M, Kaplan DH, Mi QS. microRNA miR-17-92 cluster is highly expressed in epidermal Langerhans cells but not required for its development. Genes Immun. 2014 Jan;15(1):57-61PubMed PMID: 24285176.
  13.  Chan DV, Gibson HM, Aufiero BM, Wilson AJ, Hafner MS, Mi QS, Wong HK. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immun. 2014 Jan;15(1):25-32.PMID:24173147; (involved in study conception, design, and implementation).
  14. Shi YL, Li K, Hamzavi I, Lim HW, Zhou L, Mi QS. Elevated circulating soluble interleukin-2 receptor in patients with non-segmental vitiligo in North American. J Dermatol Sci. 2013 Sep;71(3):212-4. PubMed PMID: 23870656.
  15. Mi QS, Kenny JJ. Types of tolerance seen in autoreactive phosphocholine-specific B cells are dependent on the idiotype of the receptors expressed. Cell Mol Immunol. 2013 Jul;10(4):311-6. doi: 10.1038/cmi.2013.17. PMID: 23624878.
  16. Chen WB, Gao L, Weiland M, Zhao J, Liu M, Zhou L, Mi QS. Deletion of miRNAs in bone marrow prevents streptozotocin-induced murine autoimmune diabetes but deletion of miR-155 does not. Cell Cycle. 2013 Apr 1;12(7):1151-2. PMID: 23528982.
  17. Shi YL, Weiland M, Li J, Hamzavi I, Henderson M, Huggins RH, Mahmoud BH, Agbai O, Mi X, Dong Z, Lim HW, Mi QS*, Zhou L*. MicroRNA expression profiling identifies potential Page 10 of 16.
  18. Serum biomarkers for non-segmental vitiligo. Pigment Cell Melanoma Res. 2013 May;26(3):418-21. PubMed PMID: 23470042. Co-Senior.
  19. Xu YP, Qi RQ, Chen W, Shi Y, Cui ZZ, Gao XH, Chen HD, Zhou L, Mi QS. Aging affects epidermal Langerhans cell development and function and alters their miRNA gene expression profile. Aging (Albany NY). 2012 Nov;4(11):742-54. PubMed PMID: 23178507.
  20. Mi QS, Xu YP, Qi RQ, Shi YL, Zhou L. Lack of microRNA miR-150 reduces the capacity of epidermal Langerhans cell cross-presentation. Exp Dermatol. 2012 Nov;21(11):876-7. doi: 10.1111/exd.12008. PubMed PMID: 23163655.
  21. Mi QS, Xu YP, Wang H, Qi RQ, Dong Z, Zhou L. Deletion of microRNA miR-223 increases Langerhans cell cross-presentation. Int J Biochem Cell Biol. 2013 Feb;45(2):395-400. doi: 10.1016/j.biocel.2012.11.004. Epub 2012 Nov 12. PubMed PMID: 23153510.
  22. Ozog DM, Liu A, Chaffins ML, Ormsby AH, Fincher EF, Chipps LK, Mi QS, Grossman PH, Pui JC, Moy RL. Evaluation of clinical results, histological architecture, and collagen expression following treatment of mature burn scars with a fractional carbon dioxide laser. JAMA Dermatol. 2013 Jan;149(1):50-7. doi: 10.1001/2013.jamadermatol.668. (involved in study conception, design, and implementation).
  23. Shi YL, Gu J, Park JJ, Xu YP, Yu FS, Zhou L, Mi QS. Histone deacetylases inhibitor Trichostatin A ameliorates DNFB-induced allergic contact dermatitis and reduces epidermal Langerhans cells in mice. J Dermatol Sci. 2012 Nov;68(2):99-107 PMID: 22999682.
  24. Zhang L, Yang M, Marks P, White LM, Hurtig M, Mi QS, Divine G, Gibson G. Serum non-coding RNAs as biomarkers for osteoarthritis progression after ACL injury. Osteoarthritis Cartilage. 2012 Dec;20(12):1631-7 PMID: 22944527; (involved in study conception, design, and implementation).
  25. Qu L, Liu A, Zhou L, He C, Grossman PH, Moy RL, Mi QS, Ozog D. Clinical and molecular effects on mature burn scars after treatment with a fractional CO(2) laser. Lasers Surg Med. 2012 Sep;44(7):517-24. PubMed PMID: 22907286. (involved in study conception, design, and implementation.
  26. Qu L, Wei B, Liu M, Zhang L, Xiao T, Chen HD, Zhou L, Mi QS*, He C*. A novel mutation in exon 8 of C1 inhibitor (C1INH) gene leads to abolish its physiological stop codon in a large Chinese family with hereditary angioedema type I. Exp Dermatol. 2012 Oct;21(10):788-91 PubMed PMID: 22882460. Co-Senior.
  27.  Zhou L, Li K, Shi YL, Hamzavi I, Gao TW, Henderson M, Huggins RH, Agbai O, Mahmoud B, Mi X, Lim HW, Mi QS. Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells. Pigment Cell Melanoma Res. 2012 Sep;25(5):602-11. PubMed PMID: 22591262.
  28. Xu YP, Shi Y, Cui ZZ, Jiang HH, Li L, Wang XF, Zhou L, Mi QS. TGFβ/Smad3 signal pathway is not required for epidermal Langerhans cell development. J Invest Dermatol. 2012 Aug;132(8):2106-9. PMID: 22437318; PubMed Central PMCID: PMC3398167.
  29. Mi QS, Weiland M, Qi RQ, Gao XH, Poisson LM, Zhou L. Identification of mouse serum miRNA endogenous references by global gene expression profiles. PLoS One. 2012;7(2):e31278. PubMed PMID: 22348064.
  30. Zheng Q, Zhou L, Mi QS. MicroRNA miR-150 is involved in Vα14 invariant NKTcell development and function. J Immunol. 2012 Mar 1;188(5):2118-26. PubMed PMID: 22287707.
  31. Qi R, Liu M, Gao XH, Yu FS, Chen HD, Lim HW, Zhou L, Mi QS. Histone deacetylase activity is required for skin Langerhans cell maturation and phagocytosis. J Dermatol Sci. 2012 Feb;65(2):152-5. PubMed PMID: 22222421. Page 11 of 16.
  32. Qi R, Weiland M, Gao XH, Zhou L, Mi QS. Identification of endogenous normalizers for serum microRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer. Hepatology. 2012 May;55(5):1640-2; PubMed PMID: 22213067.
  33. Mi X, He H, Deng Y, Levin AM, She JX, Mi QS*, Zhou L*. Lack of an association of miR-938 SNP in IDDM10 with human type 1 diabetes. Diabetol Metab Syndr. 2011 Oct 20;3(1):27. doi: 10.1186/1758-5996-3-27. PubMed PMID: 22014115; PubMed Co-Senior.
  34. Meng DM, Wang L, Xu JR, Yan SL, Zhou L, Mi QS. Fabp4-Cre-mediated deletion of the miRNA-processing enzyme Dicer causes mouse embryonic lethality. Acta Diabetol. 2013 Oct;50(5):823-4 PubMed PMID: 21984007.
  35. Gao N, Yin J, Yoon GS, Mi QS, Yu FS. Dendritic cell-epithelium interplay is a determinant factor for corneal epithelial wound repair. Am J Pathol. 2011 Nov;179(5):2243-53. doi: 10.1016/j.ajpath.2011.07.050. PMID: 21924232; (involved in study conception, design, and implementation).
  36.  Zhou L, Park JJ, Zheng Q, Dong Z, Mi Q. MicroRNAs are key regulators controlling iNKT and regulatory T-cell development and function. Cell Mol Immunol. 2011 Sep;8(5):380-7. doi: 10.1038/cmi.2011.27. PMID: 21822298; PubMed Central PMCID: PMC4012887.
  37. Li K, Seo KH, Gao T, Zheng Q, Qi RQ, Wang H, Weiland M, Dong Z, Mi QS*, Zhou L*. Invariant NKT cell development and function in microRNA-223 knockout mice. Int Immunopharmacol. 2011 May;11(5):561-8. PubMed PMID: 21094288. Co-Senior .
  38. Seo KH, Zhou L, Meng D, Xu J, Dong Z, Mi QS. Loss of microRNAs in thymus perturbs invariant NKT cell development and function. Cell Mol Immunol. 2010 Nov;7(6):447-53PubMed PMID: 20852654; PubMed Central PMCID: PMC4002964.
  39.  Hamrick MW, Herberg S, Arounleut P, He HZ, Shiver A, Qi RQ, Zhou L, Isales CM, Mi QS. The adipokine leptin increases skeletal muscle mass and significantly alters skeletal muscle miRNA expression profile in aged mice. Biochem Biophys Res Commun. 2010 Sep 24;400(3):379-83. PMID: 20800581.
  40. Mi QS, He HZ, Dong Z, Isales C, Zhou L. microRNA deficiency in pancreatic islet cells exacerbates streptozotocin-induced murine autoimmune diabetes. Cell Cycle. 2010 Aug 1;9(15):3127-9. PubMed PMID: 20699654.
  41. Meagher C, Beilke J, Arreaza G, Mi QS, Chen W, Salojin K, Horst N, Cruikshank WW, Delovitch TL. Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. Diabetes. 2010 Nov;59(11):2862-71. PMID: 20693344; (involved in study conception, design, and implementation).
  42. Bhatt K, Zhou L, Mi QS, Huang S, She JX, Dong Z. MicroRNA-34a is induced via p53 during cisplatin nephrotoxicity and contributes to cell survival. Mol Med. 2010 Sep-Oct;16(9-10):409-16. PubMed PMID: 20386864; (involved in study conception, design, and implementation).
  43. Wei Q, Bhatt K, He HZ, Mi QS, Haase VH, Dong Z. Targeted deletion of Dicer from proximal tubules protects against renal ischemia-reperfusion injury. J Am Soc Nephrol. 2010 May;21(5):756-61. PMID: 20360310; (involved in study conception, design, and implementation).
  44. Zhao X, He X, Han X, Yu Y, Ye F, Chen Y, Hoang T, Xu X, Mi QS, Xin M, Wang F, Appel B, Lu QR. MicroRNA-mediated control of oligodendrocyte differentiation.Neuron. 2010 Mar 11;65(5):612-26. PubMed PMID: 20223198; (involved in study conception, design, and implementation.
  45. Mi QS, Yan SL, Wang ZZ, Ding KH, Li C, Wang L, Zhou L, Yamamoto Y, Yamamoto H, Okamoto H, Isales C. Spontaneous bone loss in RIP-iNOS transgenic mouse: a mouse model for Page 12 of 16  diabetes-mediated osteopenia/osteoporosis. Cell Cycle. 2009 Dec 15;8(24):4179-81. Epub 2009 Dec 21. PubMed PMID: 19946218; PubMed Central PMCID: PMC3719381.
  46. Li C, Han L, Levin AM, Song H, Yan S, Wang Y, Wang Y, Meng D, Lv S, Ji Y, Xu X, Liu X, Wang Y, Zhou L, Miao Z, Mi QS. Multiple single nucleotide polymorphisms in the human urate transporter 1 (hURAT1) gene are associated with hyperuricaemia in Han Chinese. J Med Genet. 2010 Mar;47(3):204-10. PubMed PMID: 19833602.
  47. Zhou L, Seo KH, He HZ, Pacholczyk R, Meng DM, Li CG, Xu J, She JX, Dong Z, Mi QS. Tie2cre-induced inactivation of the miRNA-processing enzyme Dicer disrupts invariant NKT cell development. Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10266-71 PMCID: PMC2700920.
  48. Zhou L, He H, Mi JX, Li C, Lee B, Mi QS. MicroRNA genes. Ann N Y Acad Sci. 2008 Dec;1150:72-5. doi: 10.1196/annals.1447.026. PubMed PMID: 19120271.
  49. Miao ZM, Zhao SH, Yan SL, Li CG, Wang YG, Meng DM, Zhou L, Mi QS. NALP3 inflammasome functional polymorphisms and gout susceptibility. Cell Cycle. 2009 Jan 1;8(1):27-30. Epub 2009 Jan 31. PubMed PMID: 19106604.
  50. Zhou L, Wang H, Zhong X, Jin Y, Mi QS, Sharma A, McIndoe RA, Garge N, Podolsky R, She JX. The IL-10 and IFN-gamma pathways are essential to the potent immunosuppressive activity of cultured CD8+ NKT-like cells. Genome Biol. 2008;9(7):R119 PubMed PMID: 18664279; PubMed Central PMCID: PMC2530876.
  51. Zhang W, Ou G, Hamrick M, Hill W, Borke J, Wenger K, Chutkan N, Yu J, Mi QS, Isales CM, Shi XM. Age-related changes in the osteogenic differentiation potential of mouse bone marrow stromal cells. J Bone Miner Res. 2008 Jul;23(7):1118-28 PMID: 18435580; (involved in study conception, design, and implementation).
  52. Liu YY, Bi XL, Mi QS, Gu J. [Effect of arotinoid trometamol on the expression of genes in human keratinocytes]. Zhonghua Yi Xue Za Zhi. 2008 Jan 22;88(4):276-8. Chinese. PubMed PMID: 18361843. (involved in study conception, design, and implementation).
  53. Pabla N, Huang S, Mi QS, Daniel R, Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem. 2008 Mar 7;283(10):6572-83. PMID: 18162465. (involved in study conception, design, and implementation).
  54. Ding KH, Shi XM, Zhong Q, Kang B, Xie D, Bollag WB, Bollag RJ, Hill W, Washington W, Mi QS, Insogna K, Chutkan N, Hamrick M, Isales CM. Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res. 2008 Apr;23(4):536-43. PubMed PMID: 18072880; (involved in study conception, design, and implementation).
  55. Meagher C, Arreaza G, Peters A, Strathdee CA, Gilbert PA, Mi QS, Santamaria P, Dekaban GA, Delovitch TL. CCL4 protects from type 1 diabetes by altering islet beta-cell-targeted inflammatory responses. Diabetes. 2007 Mar;56(3):809-17.PubMed PMID: 17327452. (involved in study conception, design, and implementation).
  56. Mi QS, Zhou L, Grattan M, Wang ZZ, Sivilotti M, She JX, Delovitch TL. Characterization of PAF-AH Ib1 in NOD mice: PAF-AH may not be a candidate gene of the diabetes susceptibility Idd4.1 locus. Ann N Y Acad Sci. 2006 Oct;1079:147-52.PubMed PMID: 17130546.
  57.  Ly D, Mi QS, Hussain S, Delovitch TL. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J Immunol. 2006 Sep 15;177(6):3695-704. PubMed PMID: 16951329. (involved in study conception, design, and implementation).
  58. Ding KH, Wang ZZ, Hamrick MW, Deng ZB, Zhou L, Kang B, Yan SL, She JX, Stern DM, Isales CM, Mi QS. Disordered osteoclast formation in RAGE-deficient mouseestablishes an essential role for RAGE in diabetes related bone loss. BiochemBiophys Res Commun. 2006 Feb 24;340(4):1091-7. Epub 2005 Dec 27. PubMed PMID:16403440. Page 13 of 16.
  59. Yang W, Hussain S, Mi QS, Santamaria P, Delovitch TL. Perturbed homeostasis of peripheral T cells elicits decreased susceptibility to anti-CD3-induced apoptosis in prediabetic nonobese diabetic mice. J Immunol. 2004 Oct 1;173(7):4407-16. PubMed PMID: 15383571. (involved in study conception, design, and implementation).
  60. Mi QS, Ly D, Zucker P, McGarry M, Delovitch TL. Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T-cells. Diabetes. 2004May;53(5):1303-10. PubMed PMID: 15111500. (involved in study conception, design, and implementation).
  61. Chen W, Salojin KV, Mi QS, Grattan M, Meagher TC, Zucker P, Delovitch TL. Insulin-like growth factor (IGF)-I/IGF-binding protein-3 complex: therapeutic efficacy and mechanism of protection against type 1 diabetes. Endocrinology. 2004 Feb;145(2):627-38. PMID: 14617576. (involved in study conception, design, and implementation).
  62. Mi QS, Ly D, Lamhamedi-Cherradi SE, Salojin KV, Zhou L, Grattan M, Meagher C, Zucker P, Chen YH, Nagle J, Taub D, Delovitch TL. Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes. 2003 Aug;52(8):1967-75. PubMed PMID: 12882912. (involved in study conception, design, and implementation).
  63. Arreaza G, Salojin K, Yang W, Zhang J, Gill B, Mi QS, Gao JX, Meagher C, Cameron M, Delovitch TL. Deficient activation and resistance to activation-induced apoptosis of CD8+ T cells is associated with defective peripheral tolerance in nonobese diabetic mice. Clin Immunol. 2003 May;107(2):103-15. PubMed PMID: 12763479. (involved in study conception, design, and implementation).
  64. Zhou L, Népote V, Rowley DL, Levacher B, Zvara A, Santha M, Mi QS, Simonneau M, Donovan DM. Murine peripherin gene sequences direct Cre recombinase expression to peripheral neurons in transgenic mice. FEBS Lett. 2002;523(1-3):68-72. PMID: 12123806. (involved in study conception, design, and implementation).
  65. Mi QS, Rezanka LJ, Lustig A, Zhou L, Longo DL, Kenny JJ. The M603 idiotype is lost in the response to phosphocholine in terminal deoxynucleotidyl transferase-deficient mice. Eur J Immunol. 2002 Apr;32(4):1139-46. PubMed PMID: 11932921.
  66. Hu L, Rezanka LJ, Mi QS, Lustig A, Taub DD, Longo DL, Kenny JJ. T15-idiotype-negative B cells dominate the phosphocholine binding cells in the preimmune repertoire of T15i knockin mice. J Immunol. 2002 Feb 1;168(3):1273-80. PubMed PMID: 11801665. (involved in study conception, design, and implementation).
  67. Grattan M*, Mi QS*, Meagher C, Delovitch TL. Congenic mapping of the diabetogenic locus Idd4 to a 5.2-cM region of chromosome 11 in NOD mice: identification of two potential candidate subloci. Diabetes. 2002 51(1):215-23. PubMed PMID: 11756344. Co-first authors.
  68.  Zhou L, Rowley DL, Mi QS, Sefcovic N, Matthes HW, Kieffer BL, Donovan DM. Murine inter-strain polymorphisms alter gene targeting frequencies at the mu opioid receptor locus in embryonic stem cells. Mamm Genome. 2001 Oct;12(10):772-8. PubMed PMID: 11668392. (involved in study conception, design, and implementation).
  69. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite-De-Moraes M, Gouarin C, Zhu R, Hameg A, Nakayama T, Taniguchi M, Lepault F, Lehuen A, Bach JF, Herbelin A. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med. 2001 Sep;7(9):1057-62. PubMed PMID: 11533711. (involved in study conception, design, and implementation).
  70. Mi QS, Zhou L, Schulze DH, Fischer RT, Lustig A, Rezanka LJ, Donovan DM, Longo DL, Kenny JJ. Highly reduced protection against Streptococcus pneumoniae after deletion of a single Page 14 of 16  heavy chain gene in mouse. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6031-6. PubMed PMID: 10811914; PubMed Central PMCID: PMC18553.
  71.  Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A.1999 Mar 30;96(7):3775-80. PubMed PMID: 10097113; PubMed Central PMCID: PMC22370. (involved in study conception, design, and implementation).
  72. Duo FL, Zen ZX, Meng J, Mi QS, Zheng xH, Zhang M, Zhang HS, Li YZ. (1997) Treatment of 20 cases of vitiligo by auto-epidermal grafting. Huaihai Medicine. 15(3): 17-18(involved in study conception, design, and implementation).
  73. Li HL, Mi QS. (1996) Detection of chlaydia trachomatis in patients with NGU. J Taishan Med Col 17(3): 215-216.
  74. Mi QS, Chen M, Chen H-D. (1995). Study on the immune complexe cutaneous vasculitis. Chin J Immunol, 11(5):239-242.
  75. Mi QS, Chen M, Chen H-D. (1995). Immunolight and immunoelectronic microscopic identification of Langerhans cells in the subcutaneous infiltrates in erythema induratum. Chin J Dermatovenerol, 9(3):130-131.
  76. Mi QS, Zhang XZ. (1995) Study of etiology of NGU in Taian. J Taishan Med Col 16(3): 219-216.
  77. Mi QS, Gu J, Chen M. (1995). Studies on the clinic and pathology of erythema induratum. Chinese J Dermatol, 28(5):305-306.
  78. Mi QS, Pan J-C. (1995). Clinic and pathological analysis of 16 cases with pseudo-condyloma of vulva. Current Advance in obstetrics and gynecology, 4(4):315-317.
  79. Mi QS, Li H-L (1995). Treatment efficient of Ofloxacin to ureaplas urealyticum urethritis/vaginitis. Modern Applied pharmacy, 12(4);30-31.
  80. Mi QS, Gu J. (1995). The detection of anti-PPD antibodies in the serum of skin tuberculosis and its clinic significance. J Taishan Med Col, 16(2):102-105.
  81.  Mi QS, Zhou L, Chen H-D. (1996). Antisense technique and the therapy of skin virus diseases (review). Foreign Med: Dermatol,22(2):102-105.
  82.  Mi QS, Wang Y-K Chen, H-D.(1996). Effects of FK506 on dendritic epidermal T cells in mice. Chin J Dermatol, 29(6):427-429.
  83.  Mi QS, Chen M, Chen H-D. (1994). Investigation of circulating and tissue-deposited immune complexes in erythema induratum. J Taishan Med Col, 15(1):68-71.
  84. Mi QS, Chen M, Chen H-D.(1994). Immunohistochemical analysis of T cells subsets in the lesions of erythema induratum. Chin J Dermatol, 27(3):193-194.
  85. Mi QS, Chen M, Chen H-D.(1994).The detection of antibodies to mycobactrium tuberculosis in serum of erythema induratum by ELISA. Chin J Dermatol, 27(5):295-7.
  86. J. Gu, Mi QS, Chen M. (1994). Investigation on DNA of M. tuberculosis in the lesions of erythema induratum using PCR. Chin J Dermatol, 27(5):294-295(involved in study conception, design, and implementation).
  87. Mi QS, Chen M, Chen H-D. (1993). RBC immune and skin diseases (review) J Clin Dermatol, 21(3):206-208.
  88. Mi QS, Chen M, Chen H-D. (1992). Langerhans cells in the lesions of erythema induratum. Chin J Med, 72(2)104-105.
  89. Mi QS, Chen M. (1991). Study on the immunopathology of erythema induratum. Chin J Dermatol, 24(6):366-368.
  90. Li G, Gao XH, Mi QS. (2016) TGF-β1-Smad signaling pathways are not required for epidermal LC homeostasis. Oncotarget. 2016 Mar 17. doi: 10.18632/oncotarget.8167.
  91.  Zhang X, Gu J, Yu FS, Zhou L, Mi QS. TGF-β1-induced transcription factor networks in Langerhans cell development and maintenance. Allergy. 2016 Mar 7. doi: 10.1111/all.128 PMID: 26948524.
  92. Wei Q, Mi QS, Dong Z. The regulation and function of microRNAs in kidney diseases. IUBMB Life. 2013 Jul;65(7):602-14. doi: 10.1002/iub.1174. Review. PubMed PMID: 23794512.
  93. Yeon Paek S, Han L, Weiland M, Lu CJ, McKinnon K, Zhou L, Lim HW, Elder JT, Mi QS. Emerging biomarkers in psoriatic arthritis. IUBMB Life. 2015 Nov 24. doi:PubMed PMID: 26602058.
  94. Weiland M, Gao XH, Zhou L, Mi QS. (2012) Small RNA has a big impact: serum miRNAs as biomarkers for human diseases. RNA Biol, 9(6):850-9. PMID:2269955.
  95. Zhou L, Park JY, Zheng QH, Mi QS. (2011) miRNAs regulate NKT and Foxp3 Treg cell development and function. Cell Mol Immuno, 8(5):380-7.
  96. Bhatt K, Mi QS, Dong Z. microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. Am J Physiol Renal Physiol. 2011 Mar;300(3):F602-10. PubMed PMID: 21228106.
  97. Zhou L, Seo KH, Wong HK, Mi QS. MicroRNAs and immune regulatory T cells. Int  Immunopharmacol. 2009 May;9(5):524-7 PMID: 19539573.
  98. Mi QS, Meagher C, Delovitch TL. CD1d-restricted NKT regulatory cells: functional genomic analyses provide new insights into the mechanisms of protection against Type 1 diabetes. Novartis Found Symp. 2003;252:146-60; PMID: 14609217.
  99. Sharif S, Arreaza GA, Zucker P, Mi QS, Delovitch TL. Regulation of autoimmune disease by natural killer T cells. J Mol Med (Berl). 2002 May;80(5):290-300. Epub 2002 Apr 11. Review. PubMed PMID: 12021841.
  100. Mi QS, Chen M, Chen H-D. (1994). Immunosuppressant-FK506 and its clinic administration (review). International Dermatol,20(4):203-205.

Book Chapters:

  1. Zhou L, Zhong X, Mi QS and She JX (2011) Chapter: In Vitro Expanded CD8+ NKT-like Cells Possess Potent Cytotoxic and Immunosuppressive Activities. In: Advances in Medicine and Biology. Volume 14, 2011.
  2. Meagher C, Mi QS, Wagner M, Hussain S, Ly D, and Delovitch TL. Chapter: Studies on iNKT Cell Differentiation and Activation Reveal Potential Novel Therapies for Protection Against Type 1 Diabetes. In: NKT Cells. T. Yamamura and L. Croxford, ed, 2006.
  3. M. Chen, Q-S Mi. Chapter: Melanocyte Tumor, bacterial and chlamydial diseases. In: Practical histopathology of skin (ed M. Chen, et al.), Chapt 7, P63-89; Chapt. 3, P455-475. Guangdong Scientific and technological Press, 1994.

Autoimmune Journal Flyer